This is unpublished
NIRVANA: Nicotinamide Riboside in SARS-CoV-2 patients for renal protection
Completed Studies
Pinned
Principal Investigator
Bryan Kestenbaum
Status
Completed
back to page outline
Investigator
What is the study?
This study is a pilot, double-blind, placebo-controlled, multicenter, interventional clinical trial with oral nicotinamide riboside (NR) 500 mg (versus placebo) twice daily for a total of 10 days in hospitalized participants with COVID-19. Biospecimens will be collected in participants.
Study Results
Researchers have completed this study. The study found that supplementation with nicotinamide riboside (NR) and co-enzyme Q10 (COQ10) favorably altered gene sets associated with metabolism and immune/stress signaling. The paper is in-press at the Clinical Journal of the American Society of Nephrology.